Private Equity

Marina Temkin

Managers

How Anthemis shifted to managing VC funds

Over the last 10 years, the fintech venture platform has amassed $670m in AUMs and backed over 100 start-ups via the firm’s balance sheet and traditional VC vehicles.

3 min read · 12 January 2021

Managers

Franklin Templeton on investing alongside traditional VC firms

One of the world's leading mutual funds has taken advantage of its Silicon Valley location to become a meaningful VC player. Over the last five years, the firm invested nearly $1bn in late-stage and mid-stage venture capital deals.

4 min read · 24 December 2020

Managers

LPs seeking clarity over the role of SPACs

As some venture capital firms and individual VCs dip their toes into the SPAC-sponsorship waters, LPs are figuring out how to deal with potential conflicts and benefits. Some attorneys have advice, too.

9 min read · 22 December 2020

Investors

WSIB's performance shows dramatic rebound in Q2

The growth-equity and late-stage heavy portfolio of the $116bn LP cratered at the beginning of the pandemic, but it largely made up lost ground and then some by mid-year, with Sequoia Capital's recovery standing out.

3 min read · 24 November 2020

Investors

UC Regents' performance shows VC is mostly immune to pandemic's woes

Out of the dozens VC funds in California's LP portfolio, most advanced amid the pandemic and during the fiscal year ending June 30.

3 min read · 16 November 2020

Deals

Redpoint's Tomasz Tunguz on what is driving up SaaS valuations

The well-known VC and blogger discusses the reasons public markets may be willing to pay more for high-growth companies and how this impacts early-stage cloud start-ups.

4 min read · 10 November 2020

Investors

How Summit Peak turned endowment relationships into an early-stage fund of funds

Apurva Mehta and Patrick O'Connor built a top-performing emerging manager VC portfolio while they were co-CIOs of a hospital endowment in Texas. Two years ago, they converted those partnerships into an FoF.

3 min read · 04 November 2020

Deals

Less pain more gain: venBio and other VCs make great returns on migraine drugs

Biotech VCs have played a crucial role in developing medicines for the disorder before selling them to big pharma, and they've realized exceptional returns while making a difference in patients' lives.

4 min read · 03 November 2020

Managers

Investors see benefits to Zoom meetings, but miss the personal interactions

In the covid-19 era, investors say virtual board meetings provide flexibility and are more efficient. But board members say they long for the in-person interactions.

4 min read · 20 October 2020

Deals

Investors bet on computing’s quantum leap

A fully realized business model may not exist for another decade, but interest in quantum computing is soaring. Pegasus, Morpheus and Redpoint, among others, are planning for the long game.

6 min read · 14 October 2020

Showing 1 to 10 of 218 results
2345…22